Insight Molecular Diagnostics (IMDX) Return on Capital Employed (2016 - 2026)

Insight Molecular Diagnostics has disclosed Return on Capital Employed across 11 years of filings, most recently posting 38.7% for Q1 2026.

• Return on Capital Employed for Q1 2026 came in at 38.7%, down 1170.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 38.7% (down 1170.0% YoY), and the FY2025 annual result was 57.5%, down 3080.0% from the prior year.
• Return on Capital Employed came in at 38.7% for Q1 2026 at Insight Molecular Diagnostics, up from 46.32% in the prior quarter.
• In the past five years, Return on Capital Employed ranged from a high of 11.13% in Q1 2023 to a low of 68.78% in Q3 2024.
• The 5-year median for Return on Capital Employed is 32.89% (2025), against an average of 36.08%.
• Across the five-year window, Return on Capital Employed surged 3627 bps in 2023 and tumbled 5117 bps in 2024, its largest moves.
• Insight Molecular Diagnostics' Return on Capital Employed stood at 15.43% in 2022, then plunged by 129 bps to 35.38% in 2023, then climbed by 21 bps to 28.08% in 2024, then tumbled by 65 bps to 46.32% in 2025, then climbed by 16 bps to 38.7% in 2026.
• The last three Return on Capital Employed figures came in at 38.7% (Q1 2026), 46.32% (Q4 2025), and 32.89% (Q3 2025), per Business Quant data.